866-997-4948(US-Canada Toll Free)

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Oct 2017

Category :

Pharmaceutical

No. of Pages : 49 Pages

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)-Pipeline Review, H2 2017

Summary

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Type 2 Angiotensin II Receptor-Pipeline Review, H2 2017, outlays comprehensive information on the Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)-Angiotensin II receptor type 2 (AT2 receptor) is a protein encoded by the AGTR2 gene. AT2 receptor is highly expressed in the developing foetus, but its expression is very low in the cardiovascular system of the normal adult. Expression of the AT2 receptor can be modulated by pathological states associated with tissue remodeling or inflammation such as hypertension, atherosclerosis, and myocardial infarction. AT2 receptor plays an important role in vasodilatory role, and enhanced as a countervailing mechanism in cardiac hypertrophy, and in presence of vascular injury in hypertension and atherosclerosis. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Metabolic Disorders, Dermatology, Genito Urinary System And Sex Hormones, Immunology, Respiratory, Womens Health, Gastrointestinal and Oncology which include indications Diabetic Nephropathy, Idiopathic Pulmonary Fibrosis, Polycystic Ovarian Syndrome, Acute Ischemic Stroke, Atherosclerosis, Cardiomyopathy, Chronic Kidney Disease (Chronic Renal Failure), Congestive Heart Failure (Heart Failure), Dementia Associated With Alzheimers Disease, Dermatitis, Diabetic Neuropathic Pain, Hyperlipidemia, Hypertension, Inflammation, Inflammatory Pain, Kidney Fibrosis, Leiomyosarcoma, Multiple Sclerosis, Myocardial Infarction, Neuromyelitis Optica (Devics Syndrome), Non-Alcoholic Steatohepatitis (NASH), Obesity, Postherpetic Neuralgia, Prostate Cancer, Psoriasis, Pulmonary Arterial Hypertension, Rheumatoid Arthritis, Skin Inflammation, Spinal Cord Injury, Systemic Sclerosis (Scleroderma) and Type 2 Diabetes.

Furthermore, this report also reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)
- The report reviews Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)-Overview
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)-Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)-Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)-Companies Involved in Therapeutics Development
CJ HealthCare Corp
MorphoSys AG
Novartis AG
Vicore Pharma AB
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)-Drug Profiles
(amlodipine besylate + valsartan)+ atorvastatin calcium-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-21-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EMA-401-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KDT-501-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOR-107-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-6A-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize AGTR2 for Skin Inflammation and Inflammatory Pain-Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)-Dormant Products
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)-Product Development Milestones
Featured News & Press Releases
Oct 09, 2017: Clinical Potential of C21 Highlighted in Review Publications
Oct 02, 2017: Phase I extension study demonstrates beneficial effects on lipid metabolism with C21
Aug 17, 2017: Results from Extension Study with C21 Show Safety, Tolerability and Indicate Effects on lipid Metabolism
May 19, 2017: MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers
Mar 08, 2017: C21 has a strong impact on several markers in an in vitro study for pulmonary fibrosis
Mar 03, 2017: New positive study results on diabetic nephropathy with Vicore Pharmas candidate drug C21
Feb 21, 2017: MorphoSyss Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107
Sep 19, 2016: Lanthio Pharma Expands Management Team: Axel Mescheder M.D. Appointed Chief Medical Officer (CMO) of MorphoSyss Dutch Lanthipeptide Subsidiary
Aug 01, 2016: Vicore Pharma is granted orphan drug designation for C21 for the treatment of IPF
Jun 30, 2016: New research data with C21 on diabetes
Jun 15, 2016: Prestigious award for UQ superstar scientist
Jun 13, 2016: Successful conclusion of the first Phase I study with C21
Feb 10, 2015: Spinifex Pharmaceuticals Enhances CMC Team With Two Senior Appointments
May 21, 2014: Lanthio Pharma receives Dutch Government loan of up to 3.6 million to develop novel therapy for lung fibrosis
Feb 05, 2014: Spinifex Pharmaceuticals Phase 2 Results Published in The Lancet Show EMA401 to be Effective in Reducing Pain in Postherpetic Neuralgia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by CJ HealthCare Corp, H2 2017
Pipeline by MorphoSys AG, H2 2017
Pipeline by Novartis AG, H2 2017
Pipeline by Vicore Pharma AB, H2 2017
Dormant Projects, H2 2017

List of Figures
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *